Xie FF, Qian ST, Zhao HY, Liu QS. Therapeutic efficacy of immunotherapy for gastric cancer metastasis. World J Gastrointest Surg 2024; 16(12): 3881-3886 [DOI: 10.4240/wjgs.v16.i12.3881]
Corresponding Author of This Article
Qing-Sheng Liu, MM, Chief Doctor, Science and Education Section, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, No. 453 Stadium Road, Hangzhou 310007, Zhejiang Province, China. 7394822@qq.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Dec 27, 2024; 16(12): 3881-3886 Published online Dec 27, 2024. doi: 10.4240/wjgs.v16.i12.3881
Therapeutic efficacy of immunotherapy for gastric cancer metastasis
Fei-Fei Xie, Su-Ting Qian, Hao-Yu Zhao, Qing-Sheng Liu
Fei-Fei Xie, Su-Ting Qian, Hao-Yu Zhao, Department of Digestive, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Hangzhou 310007, Zhejiang Province, China
Qing-Sheng Liu, Science and Education Section, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Hangzhou 310007, Zhejiang Province, China
Author contributions: Xie FF, Qian ST, Zhao HY and Liu QS contributed to this paper; Liu QS designed the overall concept and outline of the manuscript; Xie FF and Qian ST contributed to the design and writing of the manuscript; Xie FF and Zhao HY contributed to the editing the manuscript, illustrations, and review of literature.
Supported byTraditional Chinese Medicine Science and Technology Program of Zhejiang Province and Key Medical and Health Program of Hangzhou City from Zhejiang Province Administration of Traditional Chinese Medicine, No. ZD20210047 and No. 2023ZL091.
Conflict-of-interest statement: All authors have no conflict-of-interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing-Sheng Liu, MM, Chief Doctor, Science and Education Section, Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, No. 453 Stadium Road, Hangzhou 310007, Zhejiang Province, China. 7394822@qq.com
Received: July 18, 2024 Revised: September 24, 2024 Accepted: October 22, 2024 Published online: December 27, 2024 Processing time: 133 Days and 21.6 Hours
Abstract
Gastric cancer (GC) metastasis is the main cause of poor prognosis for GC patients. In recent years, breakthroughs in immunotherapy have been made in the treatment of many kinds of cancers, providing new hope for patients with GC metastasis. This paper reviews the mechanism of immunotherapy in GC metastasis and its clinical application, and discusses and compares the research and efficacy of immunotherapy in patients with liver metastasis, lung metastasis, peritoneal metastasis and lymph node metastasis of GC. This study explores the challenges and future development directions of immunotherapy, and provides a theoretical basis and clinical guidance for the precise treatment of patients with GC metastasis.
Core Tip: Immunotherapy has gradually begun to be applied in the treatment of gastric cancer (GC) metastasis. Some studies have shown that liver metastases of advanced GC have a reduced immune response rate due to the presence of hepatic immune tolerance mechanisms. Therefore, the mechanism and efficacy of immunotherapy applied in other metastases are discussed. Previous studies have shown that immunotherapy has the best efficacy for lung metastasis and the worst efficacy for peritoneal metastasis, but it has a good safety profile and is promising for use in all GC metastases.
